Lobo S, Lobo G
Rom J Ophthalmol. 2024; 68(1):72-74.
PMID: 38617722
PMC: 11007562.
DOI: 10.22336/rjo.2024.14.
Shaheen A, Schultis S, Magraner M, Correa Z, Yannuzzi N, Greenfield D
Am J Ophthalmol Case Rep. 2023; 31:101866.
PMID: 37323588
PMC: 10265454.
DOI: 10.1016/j.ajoc.2023.101866.
Mechrgui M, Kanani S
Cureus. 2022; 14(8):e28513.
PMID: 36059357
PMC: 9420653.
DOI: 10.7759/cureus.28513.
Al Owaifeer A, AlSultan Z, Badawi A
Indian J Ophthalmol. 2022; 70(5):1491-1501.
PMID: 35502014
PMC: 9333044.
DOI: 10.4103/ijo.IJO_2134_21.
Dogan L
Beyoglu Eye J. 2022; 7(1):71-75.
PMID: 35265806
PMC: 8874252.
DOI: 10.14744/bej.2021.92905.
Topiramate-Induced Acute Myopia, Diplopia, and Photosensitivity: A Case Report.
Kocamaz M, Karadag O
Beyoglu Eye J. 2022; 4(1):42-45.
PMID: 35187431
PMC: 8842042.
DOI: 10.14744/bej.2019.07379.
Topiramate induced bilateral hypopyon uveitis and choroidal detachment: a report of two cases and review of literature.
Tyagi M, Behera S, Senthil S, Pappuru R, Ambiya V, Dikshit S
BMC Ophthalmol. 2021; 21(1):287.
PMID: 34315425
PMC: 8314555.
DOI: 10.1186/s12886-021-02050-x.
Psychopharmacological Treatment, Intraocular Pressure and the Risk of Glaucoma: A Review of Literature.
Ciobanu A, Dionisie V, Neagu C, Bolog O, Riga S, Popa-Velea O
J Clin Med. 2021; 10(13).
PMID: 34209089
PMC: 8269427.
DOI: 10.3390/jcm10132947.
Psychotropic Drug-Induced Glaucoma: A Practical Guide to Diagnosis and Management.
Jain N, Ruan C, Dhanji S, Symes R
CNS Drugs. 2021; 35(3):283-289.
PMID: 33604881
DOI: 10.1007/s40263-020-00790-w.
The Use of Topiramate for Weight Loss Causing Acute Glaucoma: A Case Report and Literature Review.
de Oliveira B, Ferrari P, Herrerias B, Hirai F, Gracitelli C
Med Hypothesis Discov Innov Ophthalmol. 2019; 8(2):116-120.
PMID: 31263722
PMC: 6592302.
Topiramate-induced acute angle closure with severe panuveitis: A challenging case report.
Mahendradas P, Parab S, Sasikumar R, Kawali A, Shetty B
Indian J Ophthalmol. 2018; 66(9):1342-1344.
PMID: 30127167
PMC: 6113830.
DOI: 10.4103/ijo.IJO_1192_17.
Case report: the role of OCT in examination of a patient with topiramate-induced acute angle closure, acute myopia and macular striae.
Osaba M, Reviglio V
Oxf Med Case Reports. 2018; 2018(7):omy030.
PMID: 30094042
PMC: 6077797.
DOI: 10.1093/omcr/omy030.
Bilateral acute myopia and angle closure glaucoma induced by Ma-huang (Ephedra): A case report.
Ryu S, Shin Y, Kang M, Cho H, Seong M
Medicine (Baltimore). 2018; 96(50):e9257.
PMID: 29390365
PMC: 5815777.
DOI: 10.1097/MD.0000000000009257.
Topiramate-induced macular neurosensory retinal detachment.
Rosenberg K, Maguire J, Benevento J
Am J Ophthalmol Case Rep. 2017; 7:31-37.
PMID: 29260075
PMC: 5722185.
DOI: 10.1016/j.ajoc.2017.05.005.
Bilateral acute angle closure glaucoma and myopic shift by topiramate-induced ciliochoroidal effusion: case report and literature review.
Lan Y, Hsieh J
Int Ophthalmol. 2017; 38(6):2639-2648.
PMID: 29063980
DOI: 10.1007/s10792-017-0740-y.
Tolerability and Safety of Commonly Used Antiepileptic Drugs in Adolescents and Adults: A Clinician's Overview.
Brodie M
CNS Drugs. 2017; 31(2):135-147.
PMID: 28101765
DOI: 10.1007/s40263-016-0406-8.
Drug-induced Angle-Closure Glaucoma.
Khurana A, Khurana B, Khurana A
J Curr Glaucoma Pract. 2016; 6(1):6-8.
PMID: 27990064
PMC: 5159452.
DOI: 10.5005/jp-journals-10008-1100.
Bilateral, Simultaneous, Acute Angle Closure Glaucoma in Pseudophakia Induced by Chlorthalidone.
Durai I, Mohan Dhavalikar M, Anand C, Ganesh V, Krishnadas R
Case Rep Ophthalmol Med. 2016; 2016:3713818.
PMID: 27274878
PMC: 4871965.
DOI: 10.1155/2016/3713818.
Evaluation of Ocular Side Effects in the Patients on Topiramate Therapy for Control of Migrainous Headache.
Hesami O, Hosseini S, Kazemi N, Hosseini-Zijoud S, Moghaddam N, Assarzadegan F
J Clin Diagn Res. 2016; 10(3):NC01-4.
PMID: 27134906
PMC: 4843292.
DOI: 10.7860/JCDR/2016/16263.7339.
Anterior segment optical coherence tomography in angle closure glauma with topiramat use.
Shubhakaran K
Indian J Ophthalmol. 2015; 62(12):1174-5.
PMID: 25579367
PMC: 4313506.
DOI: 10.4103/0301-4738.149155.